RT Journal Article
SR Electronic
T1 HPV vaccination of girls in the German model region Saarland: Insurance data-based analysis and identification of starting points for improving vaccination rates
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.10.01.21264397
DO 10.1101/2021.10.01.21264397
A1 Anna Marthaler
A1 Barbara Berkó-Göttel
A1 Jürgen Rissland
A1 Jakob Schöpe
A1 Emeline Taurian
A1 Hanna Müller
A1 Gero Weber
A1 Stefan Lohse
A1 Thomas Lamberty
A1 Bernd Holleczek
A1 Harry Stoffel
A1 Gunter Hauptmann
A1 Martin Giesen
A1 Christiane Firk
A1 Alexandra Schanzenbach
A1 Florian Brandt
A1 Heike Hohmann
A1 Quirin Werthner
A1 Dominik Selzer
A1 Thorsten Lehr
A1 Stefan Wagenpfeil
A1 Sigrun Smola
YR 2021
UL http://medrxiv.org/content/early/2021/10/01/2021.10.01.21264397.abstract
AB In Germany, the incidence of cervical cancer, a disease caused by human papillomaviruses (HPV), is higher than in neighboring European countries. HPV vaccination has been recommended for girls since 2007. However, it continues to be significantly less well received than other childhood vaccines, so its potential for cancer prevention is not fully realized.To find new starting points for improving vaccination rates, we analyzed pseudonymized routine billing data from statutory health insurers in the PRÄZIS study in the federal state Saarland serving as a model region. We show that lowering the HPV vaccination age to 9 years led to more completed HPV vaccinations already in 2015. Since then, HPV vaccination rates and the proportion of 9-to 11-year-old girls among HPV-vaccinated females have steadily increased. However, HPV vaccination rates among 15-year-old girls in Saarland remained well below 50% in 2019. Pediatricians vaccinated the most girls overall, with a particularly high proportion at the recommended vaccination age of 9-14 years, while gynecologists provided more HPV catch-up vaccinations among 15-17-year-old girls, and general practitioners compensated for HPV vaccination in Saarland communities with fewer pediatricians or gynecologists. We also provide evidence for a significant association between attendance at the U11 or J1 medical check-ups and HPV vaccination. In particular, participation in HPV vaccination is high on the day of U11. However, obstacles are that U11 is currently not funded by all statutory health insurers and there is a lack of invitation procedures for both U11 and J1, resulting in significantly lower participation rates than for the earlier U8 or U9 screenings, which are conducted exclusively with invitations and reminders.Based on our data, we propose to restructure U11 and J1 screening in Germany, with mandatory funding for U11 and organized invitations for HPV vaccination at U11 or J1 for both boys and girls.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by a grant of the Gemeinsamer Bundesausschuss Innovationsfonds (PRAEZIS grant no. 01VSF16050) to SS (project leader), BH, GH, CF, AS, TLe, SW and the Saarland Staatskanzlei (Sinfonica grant no. WT/2 LFFP 14/15) to SS. PRAEZIS (01VSF16050): https://innovationsfonds.g-ba.de Sinfonica (WT/2 LFFP 14/15: https://www.saarland.de/stk/DE/portale/wissenschaftforschungtechnologie/informatione n/foerderung/landesforschungsfoerderung/landesforschungsfoerderung_node.html PRAEZIS (01VSF16050): No role in the study design, data collection and analysis, or preparation of the manuscript Sinfonica (WT/2 LFFP 14/15): No role in the study design, data collection and analysis, decision to publish, or preparation of the manuscriptAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:In this study, we analyzed pseudonymized prospective and retrospective statutory health insurance billing data. The Ethics Committee of the Saarland Medical Association reviewed, approved all study procedures, and waived the requirement for informed consent (Ethikkommission Kenn-Nr. 186/17). All procedures were performed in accordance with the recommendations of the data protection authorities (Saarland University, Saarland Ministry of Social Affairs, Health, Women and Family Affairs, Saarland Independent Data Protection Center).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files.